Cargando…

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy

The advent of anti-vascular endothelial growth factor (VEGF) agents has revolutionized the treatment of retinal neovascular diseases including neovascular age-related macular degeneration (nAMD), a leading cause of irreversible blindness. Multiple agents and methods for drug delivery are emerging to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Archana A, Finn, Avni P, Sternberg Jr, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9529225/ https://www.ncbi.nlm.nih.gov/pubmed/36199631 http://dx.doi.org/10.2147/DDDT.S368963

Ejemplares similares

Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan
por: Mukai, Ryo, et al.
Publicado: (2023)

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
por: Ferro Desideri, Lorenzo, et al.
Publicado: (2023)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
por: Tamiya, Ryosuke, et al.
Publicado: (2023)

Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
por: Kikuchi, Yusuke, et al.
Publicado: (2023)

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
por: Khanani, Arshad M., et al.
Publicado: (2021)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Leung, Ella H, et al.
Publicado: (2023)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)

Faricimab for Treatment-Resistant Diabetic Macular Edema
por: Rush, Ryan B, et al.
Publicado: (2022)

Future Therapies of Wet Age-Related Macular Degeneration
por: Ishikawa, Makoto, et al.
Publicado: (2015)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
por: Larsen, Helene O., et al.
Publicado: (2023)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
por: Khanani, Arshad M., et al.
Publicado: (2023)

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Imaging of Wet Age-Related Macular Degeneration
por: Kenan, Damer
Publicado: (2016)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Systemic Dendrimer-Peptide Therapies for Wet Age-Related Macular Degeneration
por: Wu, Tony, et al.
Publicado: (2023)

Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History
por: Inoda, Satoru, et al.
Publicado: (2023)

Pegaptanib in the treatment of wet, age-related macular degeneration
por: Vinores, Stanley A
Publicado: (2006)

Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration
por: Garba, Adinoyi O., et al.
Publicado: (2010)

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema
por: Kusuhara, Sentaro, et al.
Publicado: (2023)

One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema
por: Rush, Ryan B
Publicado: (2023)

Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema
por: Takamura, Yoshihiro, et al.
Publicado: (2023)

Efficacy of ranibizumab combined with photodynamic therapy on wet age-related macular degeneration
por: Chen, Ling, et al.
Publicado: (2020)

Wet age related macular degeneration management and follow-up
por: Alexandru, Malciolu Radu, et al.
Publicado: (2016)

Hypertension affects the treatment of wet age‐related macular degeneration
por: Wang, Ting, et al.
Publicado: (2021)

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
por: Sahni, Jayashree, et al.
Publicado: (2020)

Macular morphology and response to ranibizumab treatment in patients with wet age-related macular degeneration
por: Dervenis, Nikolaos, et al.
Publicado: (2016)

YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
por: Eter, Nicole, et al.
Publicado: (2021)

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
por: Khanani, Arshad M., et al.
Publicado: (2020)

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials
por: Takahashi, Kanji, et al.
Publicado: (2023)

Evaluation of circulating miRNAs in wet age-related macular degeneration
por: Ertekin, Sevda, et al.
Publicado: (2014)

Evaluation of cardiovascular biomarkers in patients with age-related wet macular degeneration
por: Keles, Sadullah, et al.
Publicado: (2014)

Wide-Field Fluorescein Angiography in Wet Age-Related Macular Degeneration
por: Madhusudhan, Savitha, et al.
Publicado: (2014)

Stereotactic radiotherapy for wet age-related macular degeneration: current perspectives
por: Neffendorf, James E, et al.
Publicado: (2015)

Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration
por: Korb, Christina A., et al.
Publicado: (2023)

Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy
por: Faulkner, Michele A
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bbunn615cj9kmq5so35m28eph8